Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$6.14 USD
0.00 (0.00%)
Updated Aug 28, 2024 01:10 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Price, Consensus and EPS Surprise
APLT 6.14 0.00(0.00%)
Will APLT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLT
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
Other News for APLT
Applied Therapeutics price target raised by $1 at Citi, here's why
Franklin Biotechnology Discovery Fund Q2 2024 Commentary
Applied Therapeutics management to meet virtually with William Blair
Applied Therapeutics management to meet virtually with William Blair
Optimistic Buy Rating for Applied Therapeutics Amid Positive Drug Approval Prospects